Mechelen, Belgium; 24 May 2011- Galapagos NV (Euronext: GLPG) announced that four abstracts have been selected for presentation at the Annual European Congress of Rheumatology (EULAR) taking place 25-28 May 2011 at the ExCel Congress Centre in London. Presentations will include pre-clinical and early clinical findings on two programs: GLPG0634, a selective JAK1 inhibitor being developed for rheumatoid arthritis, and GLPG0259, a small molecule inhibitor of the kinase MAPKAPK5.
The full abstracts can be accessed through the EULAR conference website or www.eular.org. After the presentation and posters are presented they will be available in PDF format on Galapagos' website: www.glpg.com.
For more information:
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240